Avandia (rosiglitazone) increases the risk of heart attack

Patients are asking about the news that Avandia (rosiglitazone) increases the risk of heart attack.

A new meta-analysis suggests a higher risk of heart attacks in patients taking Avandia compared to other meds or placebo.

Experts crunching the same numbers come up with differing conclusions and point out the study's shortcomings. The complicated statistics are explored in our Detail-Document.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote